Healthcare - Biotechnology - NASDAQ - US
$ 0.0001
0 %
$ 4.46 K
Market Cap
0.0
P/E
CASH FLOW STATEMENT
-29.1 M
OPERATING CASH FLOW
-82 K
INVESTING CASH FLOW
14.8 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aridis Pharmaceuticals, Inc.
| Net Income | -30.4 M |
| Depreciation & Amortization | 487 K |
| Capital Expenditures | -82 K |
| Stock-Based Compensation | 1.48 M |
| Change in Working Capital | -1.3 M |
| Others | 3.21 M |
| Free Cash Flow | -29.2 M |
Cash Flow
Millions
| Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (30.4) | (42.2) | (22.3) | (29.7) | (22.1) | (24.7) | (8.4) |
| Depreciation & Amortization | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 62 K | 23 K |
| Deferred Income Tax | 0 | (0.7) | 0 | 0 | 0 | 0 | 0.2 |
| Stock Based Compensation | 1.5 | 2.3 | 2.1 | 2.0 | 1.7 | 1.6 | 0.9 |
| Other Operating Activities | 0.6 | 6.8 | 9 K | 1.0 | (1.6) | 5.2 | 0.4 |
| Change in Working Capital | (1.3) | 10.5 | (0.6) | 18.2 | (2.5) | 0.3 | 0.9 |
| Cash From Operations | (29.1) | (22.9) | (20.5) | (8.2) | (24.3) | (17.6) | (6.1) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 82 K | (0.5) | (0.4) | (0.2) | (0.7) | (0.7) | 15 K |
| Other Items | 0 | 0 | 0 | 0 | (1.0) | 0 | 0 |
| Cash From Investing Activities | 82 K | (0.5) | (0.4) | (0.2) | (1.7) | (0.7) | 15 K |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 3.2 | 5.0 | 0.7 | 0 | 0 | 0 | (0.3) |
| Dividends Paid | 0 | (4.1) | 0 | 0 | (1.4) | 0 | 0 |
| Other Financing Activities | (1.0) | 4.1 | 14 K | 35 K | 1.4 | 21.1 | 25.8 |
| Cash From Financing Activities | 14.8 | 34.7 | 8.7 | 5.0 | 25.1 | 21.1 | 25.5 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (14.4) | 11.3 | (12.2) | (3.3) | (0.9) | 2.8 | 19.4 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (29.2) | (23.5) | (20.8) | (8.3) | (24.9) | (18.3) | (6.1) |